Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids

Basit Öğe Kaydı
dc.authoridSevinç, Alper/0000-0002-0499-8918
dc.authoridTÜRK, Haci Mehmet/0000-0003-2206-8148;
dc.authorwosidSevinç, Alper/KPA-4519-2024
dc.authorwosidTÜRK, Haci Mehmet/B-5013-2015
dc.authorwosidSari, Ramazan/C-2868-2016
dc.authorwosidSevinc, Alper/KFQ-6440-2024
dc.contributor.authorSevinc, A
dc.contributor.authorBuyukberber, S
dc.contributor.authorSari, R
dc.contributor.authorKiroglu, Y
dc.contributor.authorTurk, HM
dc.contributor.authorAtes, M
dc.date.accessioned2024-08-04T20:12:09Z
dc.date.available2024-08-04T20:12:09Z
dc.date.issued2000
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjective. Serum CA-125, an ovarian tumor marker, is used especially in the follow-up of ovarian cancer for monitoring the efficacy of therapy and for early detection of recurrence. A number of benign gynecologic as well as benign and malignant nongynecologic conditions are associated with elevated serum CA-125 levels. Malignant and nonmalignant serosal fluids were also found to be associated with high serum levels of CA-125, suggesting that the presence of fluid in the serosal cavities may stimulate its release. Methods. We performed a clinical study in 39 patients (21 females, 18 males) on chronic hemodialysis who were divided into two groups based on the presence of fluid in the serosal cavities (peritoneum, pleura, or pericardium) without clinical and radiologic evidence of neoplasia. There were 26 patients (16 females, 10 males) aged 50.11 +/- 13.86 years (range, 20-76 years) in the serosal fluid-negative group (group 1) and 13 patients (8 females, 5 males) aged 45.30 +/- 18.84 years (range, 17-73 years) in the serosal fluid-positive group (group 2). The control group consisted of 52 healthy volunteers (30 females, 22 males) aged 44.19 +/- 12.59 years (range, 19-68 years). Results. Significantly elevated serum CA-125 levels were found in hemodialysis patients with serosal fluid (P < 0.05) when compared with both the hemodialysis patients without serosal fluid and the control group. There was no statistically significant difference between the control group and the patients without serosal fluids (P > 0.05). Conclusion. Although CA-125 can be considered a reliable tumor marker in patients undergoing hemodialysis, it should be interpreted with caution in patients with serosal fluids. (C) 2000 Academic Press.en_US
dc.identifier.doi10.1006/gyno.2000.5776
dc.identifier.endpage257en_US
dc.identifier.issn0090-8258
dc.identifier.issue2en_US
dc.identifier.pmid10785474en_US
dc.identifier.scopus2-s2.0-0034070198en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage254en_US
dc.identifier.urihttps://doi.org/10.1006/gyno.2000.5776
dc.identifier.urihttps://hdl.handle.net/11616/93251
dc.identifier.volume77en_US
dc.identifier.wosWOS:000087028300007en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAcademic Press Incen_US
dc.relation.ispartofGynecologic Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCA-125en_US
dc.subjecthemodialysisen_US
dc.subjectascitesen_US
dc.subjectpleuraen_US
dc.subjectpericardiumen_US
dc.titleElevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluidsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu